Cover of: Pulmonary Surfactant | Jacques R. Bourbon Read Online

Pulmonary Surfactant Biochemical, Functional, Regulatory, and Clinical Concepts by Jacques R. Bourbon

  • 383 Want to read
  • ·
  • 87 Currently reading

Published by CRC .
Written in English


  • Respiratory medicine,
  • Pediatrics,
  • Pulmonary surfactant,
  • Respiratory Diseases,
  • Respiratory System Physiology,
  • Medical,
  • Medical / Nursing,
  • therapeutic use,
  • Health/Fitness,
  • Pulmonary & Thoracic Medicine,
  • Medical / Pulmonary & Thoracic Medicine,
  • Physiology,
  • Pulmonary Surfactants,
  • Respiratory Distress Syndrome

Book details:

The Physical Object
Number of Pages450
ID Numbers
Open LibraryOL8260969M
ISBN 10084936924X
ISBN 109780849369247

Download Pulmonary Surfactant


Since the first edition of this book was published in , there has been a spectacular development in both basic research on the pulmonary surfactant system and the clinical use of surfactant for treatment of lung diseases hence the addition of the subtitle indicating the expansion of knowledge in the field and the expanded information Cited by: Genre/Form: Surfactant-System: Additional Physical Format: Online version: Pulmonary surfactant. Amsterdam ; New York: Elsevier ; New York, NY, USA: Sole. Pulmonary surfactant is composed of approximately 90% lipids and 10% proteins. Type II pneumocytes secrete surfactant, and it gets metabolized by macrophages. The proteins found in surfactant play a diverse range of roles, many of which are the topic of : Benjamin D. Seadler, Sandeep Sharma. The pulmonary surfactant system. Pulmonary surfactant is a complex mixture of phospholipids (PL), neutral lipids [particularly cholesterol (Chol)], and proteins. The PL are assembled in the endoplasmic reticulum and the Golgi apparatus of alveolar type II cells and are stored in lamellar bodies until exocytosis (Fig. 1).Cited by:

Pulmonary surfactant is a complex mixture of phospholipids and proteins that functions to reduce surface tension at the alveolar air interface preventing atelectasis. Deficiency of pulmonary surfactant is the principal cause of respiratory distress syndrome in premature infants (Whitsett and Weaver, ). Surfactant therapy in combination with nasal continuous positive airway pressure (CPAP) has been shown to be superior to nasal CPAP alone in a small study of neonates with RDS. Natural human pulmonary surfactant is secreted by the lamellar bodies of alveolar type-II cells, and is first synthesized in the fetus after 24—28 weeks of gestation. Lung surfactants are made from animal lung extract and contain phospholipids. Natural surfactant is produced by the alveolar cells in the lungs and line mainly the alveoli and small bronchioles, and prevents the alveoli from collapsing. Lung surfactant makes it easier for oxygen to penetrate the lung surface lining and move into the blood. Book Description. This book represents a comprehensive update on pulmonary surfactant by merging classical knowledge with new information. Topics include surfactant secretion and alveolar processing and recycling; physical bases and different theoretical models of the physiological mechanism for pulmonary surfactant action; recent findings on surfactant-like .

As described earlier, surfactant helps in reducing surface tension and thereby increases compliance of the lung. An absence of the surfactant leads to a decrease in pulmonary compliance, and this condition is called Newborn respiratory distress syndrome. It is fatal and requires aggressive measures by continuous positive pressure breathing. Pulmonary surfactant is a lipoprotein complex responsible for preventing the collapse of alveoli and increasing lung compliance.[1]Therapeutically, exogenous surfactant administration, or surfactant replacement therapy(SRT), is considered in preterm infants with radiographic (small volume lungs, haziness/ ground-glass appearance, air bronchograms and loss of cardiac .   Summary Pulmonary surfactant is a complex mixture of specific lipids, proteins and carbohydrates, which is produced in the lungs by type II alveolar epithelial cells. The mixture is surface active and acts to decrease surface tension at the air–liquid interface of the by: 4. Pulmonary surfactant is a lipoprotein complex responsible for preventing the collapse of alveoli and increasing lung compliance.[1]Therapeutically, exogenous surfactant administration, or.